Why Abbott Stock Dipped Despite Solid Q3 Earnings: Key Analysis

Why Abbott’s Stock Fell After Meeting Expectations

Investors reacted sharply to Abbott Laboratories’ Q3 2025 earnings, sending shares down 3-4% despite the company hitting adjusted EPS targets of $1.30. This disconnect stems from a nuanced market focus shifting from bottom-line performance to structural risks. Revenue came in at $11.37 billion—a marginal $30 million miss versus the $11.4 billion consensus. While this shortfall was minor (just -0.26%), it spotlighted weaknesses in China’s diagnostics segment under Volume-Based Procurement (VBP) pressures. After analyzing the earnings discussion, I believe the market used this slight miss to scrutinize deeper vulnerabilities, overshadowing operational wins like a 40-basis-point margin improvement to 23.0%. Management’s reaffirmed guidance signals confidence, but investors need context on why sentiment turned negative.

Dissecting the Q3 Segment Performance: Medtech Shines, Diagnostics Stumbles

Medtech: The Unquestioned Growth Engine

Abbott’s medical devices segment delivered a standout performance with $5.45 billion in sales, achieving 12.5% organic growth that crushed expectations. This wasn’t driven by a single product but broad-based strength:

• Diabetes Care: FreeStyle Libre sales surged 17.2% to $2.0 billion, cementing its dominance in continuous glucose monitoring.
• Electrophysiology & CRM: The AVEIR leadless pacemaker fueled 13% growth in cardiac rhythm management, with management highlighting its potential to redefine care standards.
• Structural Heart: Robust demand across valves and clip systems, supported by recent approvals like TriClip in Japan.

Diagnostics: China’s VBP Drag and the COVID Cliff

Diagnostics revenue fell year-over-year, but the core issue wasn’t the expected COVID testing decline ($69M vs. $265M in Q3 2024). Excluding COVID sales, organic growth was flat at just 0.4%—far below historical trends. Volume-Based Procurement (VBP) in China is the critical factor:

• VBP forces steep price cuts in exchange for market volume, pressuring Abbott’s core lab business.
• Outside China, diagnostics grew healthily: core lab +7%, point-of-care +8%.
  This regional disparity reveals a structural, policy-driven headwind rather than broad demand erosion.

Nutrition and Pharmaceuticals: Steady Contributions

• Nutrition: 4.0% organic growth, with adult nutrition (Ensure/Glucerna) up 5.4% offsetting an 8.4% decline in U.S. pediatric sales due to competitor supply recovery and WIC contract losses.
• Established Pharmaceuticals: 7.1% growth, powered by 11%+ gains in emerging markets like Asia and Latin America for branded generics.

Management’s Confidence: 2025 Guidance and 2026 Catalysts

Reaffirmed Outlook Amid Market Skepticism

Despite the stock reaction, Abbott held firm on full-year 2025 guidance:

• Adjusted EPS narrowed to $5.12–$5.18 (midpoint unchanged).
• Organic sales growth outlook maintained at 7.5–8.0% ex-COVID testing.
  CEO Robert Ford emphasized comfort with 2026 consensus estimates, projecting:
• High-single-digit revenue growth.
• Continued double-digit EPS expansion.

Three Pillars Supporting Long-Term Growth

1. Product Momentum: Libre, TriClip, and electrophysiology devices sustaining growth.
2. New Launches: Volt PFA catheter (U.S. launch in 2026) integrates with Abbott’s mapping system for conscious sedation procedures—reducing hospital costs.
3. Easing Headwinds: China VBP impact and COVID comparisons diminish by 2026.

The Hidden Catalyst: Non-Insulin CGM Coverage Expansion

Game-Changing Regulatory Opportunity

Management highlighted ongoing CMS discussions to cover CGMs like Libre for type 2 diabetics not using insulin—a massive untapped population. Critically:

• This potential expansion is NOT baked into 2026 forecasts.
• Approval could occur in 2026, adding significant upside to growth projections.
• Coverage would unlock accessibility for millions, accelerating Libre adoption beyond current trajectories.

Why This Isn’t Just Speculation

• CMS policy shifts follow clinical evidence demonstrating CGM benefits for all diabetics.
• Abbott’s real-world data (e.g., Libre’s outcomes studies) strengthens the coverage argument.
• Competitors are lobbying for similar expansions, signaling industry-wide expectation.

Investor Action Plan: Monitoring Abbott’s Turning Points

Key Metrics to Watch

• China Diagnostics: Monthly VBP policy updates and volume trends.
• Medtech Innovation: U.S. adoption rates for Volt PFA and TriClip.
• CMS Developments: Formal proposals for non-insulin CGM coverage.

Immediate Steps for Shareholders

1. Revisit diagnostic segment margins quarterly for VBP adaptability signs.
2. Track Libre’s market share in new geographies like India and Brazil.
3. Review CMS meeting minutes for CGM coverage language changes.

Abbott’s dividend aristocrat status—53 years of consecutive increases—provides stability, but the real growth levers are medtech innovation and regulatory catalysts. That tiny revenue miss exposed China’s risks, yet the company’s pipeline and operational efficiency justify its double-digit EPS targets. The CGM coverage opportunity could be transformative if realized, making Abbott a compelling watch despite near-term noise.

When evaluating Abbott’s 2026 potential, which factor concerns you most: China’s VBP impact or delays in CMS CGM coverage? Share your perspective below.